Castle will use the proceeds to accelerate marketing and new product development related to its molecular prognostic tests for patients with underserved cancers.
This week's news includes Ambry Genetics, DNAstack, Protea Biosciences Group, Exosome Diagnostics, BGI Europe, and Castle Biosciences.
The Medicare contractor is proposing to not cover Vectra DA, but to extend coverage for Prolaris, Xpresys, and DecisionDx-UM under specific circumstances.
The company's new $14 million facility refinances its original $6 million loan, and adds capital for new growth.
The first tranche of the targeted $20 million financing round will be used to accelerate adoption of the company's melanoma test.
The financing will go toward commercial and clinical activities to increase adoption of the company's DecisionDx-Melanoma test.
The study demonstrated that the company's DecisionDx-Melanoma assay better predicts the risk of metastasis in patients with localized disease than clinical staging alone.
Survey results reflect strong penetration of Castle Biosciences' uveal melanoma test among specialists as the company plans a future focus on more prevalent diseases.
NEW YORK (GenomeWeb) – Cancer molecular diagnostics firm Castle Biosciences today said that it raised $11.8 million in a Series E financing round.
Originally published May 6. NEW YORK (GenomeWeb) – Castle Biosciences presented data from two validation studies involving its DecisionDx - Mesothelioma molecular test at the American Association for Thoracic Surgery annual meeting.
NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.
According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.
A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.
In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.